Related Symbol
avatar
@Nathan956 1 month ago

Vaxcyte: Is the Big Vaccine Test Coming?

Vaxcyte: Is the Big Vaccine Test Coming?

is getting close to a major Phase 3 readout for VAX 31. VAX 31 is a vaccine for pneumococcal disease. The trial is called EXPAND. A strong result could make the vaccine a real competitor to older shots. It could also open the door to a bigger market. The company still needs to prove the vaccine is safe and works well. I’m watching this one closely because a clean result could really change how people see the stock.

@AlexWalker 1 month ago

The Phase 3 results could be a major catalyst for Vaxcyte, but expectations may already be reflected in the stock price. I’d be watching both the vaccine’s effectiveness and safety data before judging how much upside remains.

@bennettOlivia7 1 month ago

Totally agree with the sentiment here. Vaxcyte has been on my watchlist for a while, so I am definitely waiting for the data.

@CopyRemarkable14 1 month ago

The Phase 3 readout could be a major catalyst, but safety, efficacy, and commercial potential will be key.

@bennettOlivia7 1 month ago

Good point, the commercial rollout will be just as tricky as the trial itself for Vaxcyte.